Metabolic Diseases  >>  Suglat (ipragliflozin)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
NCT01302145: Drug to Drug Interaction Study With ASP1941 and Metformin

Checkmark P1 data
Jul 2012 - Jul 2012: P1 data
Completed
1
36
Europe
ASP1941, Metformin, Placebo
Astellas Pharma Inc
Type 2 Diabetes Mellitus
12/09
12/09
NCT01023945: A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus

Checkmark Data
Jun 2011 - Jun 2011: Data
Completed
1
30
Japan
ASP1941, Placebo
Astellas Pharma Inc
Type 2 Diabetes Mellitus
03/10
03/10
NCT01097681: A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment

Checkmark Data
Jun 2011 - Jun 2011: Data
Checkmark Data
: Data
Completed
1
25
Japan
ASP1941
Astellas Pharma Inc
Type 2 Diabetes Mellitus
06/10
06/10
NCT01302028: Renal Impairment Study With ASP1941

Completed
1
40
Europe, RoW
ASP1941
Astellas Pharma Inc
Type 2 Diabetes Mellitus
06/10
06/10
NCT01611363: A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Checkmark EASD 2013
Jul 2013 - Jul 2013: EASD 2013
Completed
1
44
Europe
ASP1941, Ipragliflozin, Placebo
Astellas Pharma Europe B.V.
Type 2 Diabetes Mellitus
02/12
02/12

Download Options